-
公开(公告)号：EP3302484B1
公开(公告)日：2020-09-16
申请号：EP16804001.2
申请日：2016-05-24
发明人： SHEN, Dong-Ming , DWYER, Michael, P. , SINZ, Christopher, J. , WANG, Deping , STACHEL, Shawn, J. , PAONE, Daniel, V. , FORSTER, Ashley , BERGER, Richard , SHIPE, William, D. , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei , FU, Jianmin , GUO, Zhigang , LI, Haitang , BO, Yingjian
IPC分类号： A61K31/519 , A61P25/28 , C07D487/04
-
2.发明公开
公开(公告)号：EP3302484A1
公开(公告)日：2018-04-11
申请号：EP16804001.2
申请日：2016-05-24
发明人： SHEN, Dong-Ming , DWYER, Michael, P. , SINZ, Christopher, J. , WANG, Deping , STACHEL, Shawn, J. , PAONE, Daniel, V. , FORSTER, Ashley , BERGER, Richard , SHIPE, William, D. , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei , FU, Jianmin , GUO, Zhigang , LI, Haitang , BO, Yingjian
IPC分类号： A61K31/519 , A61P25/28 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28
摘要： The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
3.发明授权FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权融合四十六烷衍生物及其用于治疗病毒疾病的方法
公开(公告)号：EP2621279B1
公开(公告)日：2018-04-04
申请号：EP11833017.4
申请日：2011-09-28
发明人： COBURN, Craig, A. , LAVEY, Brian, J. , DWYER, Michael, P. , KOZLOWSKI, Joseph, A. , ROSENBLUM, Stuart, B.
IPC分类号： C07D405/14 , C07D403/14 , C07D493/04 , C07D498/04 , A61K31/4178 , A61P31/14
CPC分类号： A61K31/553 , A61K31/4178 , A61K31/5517 , A61K45/06 , C07D403/14 , C07D405/14 , C07D487/04 , C07D493/04 , C07D498/04 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/395
摘要： The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A′, B, G, R1, U, V, W, W′, X, X′, Y and Y′ are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.
-
4.发明公开SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS 审中-公开取代的3-氮杂双环[3,1,0-]己烷衍生物作为CCR2拮抗剂
公开(公告)号：EP2685828A1
公开(公告)日：2014-01-22
申请号：EP12757995.1
申请日：2012-03-14
发明人： NAIR, Anilkumar, G. , DUCA, Jose, S. , DWYER, Michael, P. , KOZLOWSKI, JOseph, A. , ROSENBLUM, Stuart, B.
CPC分类号： C07D209/52 , C07D401/06 , C07D401/08 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/08 , C07D409/04 , C07D409/08 , C07D409/14 , C07D413/04 , C07D417/08 , C07D471/04
摘要： Disclosed are CCR2 antagonists of Formula (I) or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.
-
公开(公告)号：EP3319966B1
公开(公告)日：2020-01-29
申请号：EP16818525.4
申请日：2016-06-27
发明人： STACHEL, Shawn, J. , SINZ, Christopher, J. , CHEN, Yili , WILSON, Jonathan, E. , DWYER, Michael, P. , PAONE, Daniel, V. , XU, Shimin
IPC分类号： C07D487/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61K31/519 , A61K31/53
-
公开(公告)号：EP3319966A1
公开(公告)日：2018-05-16
申请号：EP16818525.4
申请日：2016-06-27
发明人： STACHEL, Shawn, J. , SINZ, Christopher, J. , CHEN, Yili , WILSON, Jonathan, E. , DWYER, Michael, P. , PAONE, Daniel, V. , XU, Shimin
IPC分类号： C07D487/04 , A61K31/53 , C07D231/56 , C07D253/06 , C07D253/065 , C07D253/075
摘要： The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
7.发明公开SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 审中-公开含SILY的杂环化合物及其用于治疗病毒疾病的方法
公开(公告)号：EP2755981A1
公开(公告)日：2014-07-23
申请号：EP12831707.0
申请日：2012-09-11
发明人： DWYER, Michael, P. , KEERTIKAR, Kartik, M. , ZENG, Qingbei , MAZZOLA, Robert, D., Jr. , YU, Wensheng , TANG, Haiqun , KIM, Seong Heon , TONG, Ling , ROSENBLUM, Stuart, B. , KOZLOWSKI, Joseph, A. , NAIR, Anilkumar Gopinadhan
IPC分类号： C07F7/10
CPC分类号： C07F7/10 , A61K31/695 , A61K45/06 , A61K2201/094 , A61K2300/00 , C07F7/0816
摘要： The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及式（I）的新的含甲硅烷基的杂环化合物及其药学上可接受的盐，其中A，B，C，D，E，F和L如本文所定义。 本发明还涉及包含至少一种含甲硅烷基的杂环化合物的组合物，以及使用含甲硅烷基的杂环化合物治疗或预防患者中HCV感染的方法。
-
8.发明授权NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS 有权细胞周期检查点和新的调节剂及其使用结合CHECKPOINT激酶抑制剂
公开(公告)号：EP2217611B1
公开(公告)日：2013-07-31
申请号：EP08847725.2
申请日：2008-11-05
发明人： GUZI, Timothy, J. , PARRY, David, A. , LABROLI, Marc, A. , DWYER, Michael, P. , PARUCH, Kamil , ROSNER, Kristen, E. , SHEN, Ruichao , POPOVICI-MULLER, Janeta
IPC分类号： C07H19/073 , C07H19/067 , A61K31/7068 , A61P35/00
CPC分类号： C07H19/067 , C07H19/073
-
9.发明公开
公开(公告)号：EP3313852A1
公开(公告)日：2018-05-02
申请号：EP16815100.9
申请日：2016-06-20
发明人： MORRIELLO, Gregori J. , CHANG, Lehua , FORSTER, Ashley , CHEN, Yili , DWYER, Michael, P. , BERGER, Richard , WANG, Ming , NANDA, Kausik K. , BUNDA, Jaime L. , SHIPE, William D.
IPC分类号： C07D498/04 , C07D491/04 , C07D495/04
CPC分类号： C07D498/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/28 , C07D473/34 , C07D487/04
摘要： The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
10.发明公开FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权简明TETRA环状衍生物及使用方法进行病毒疾病治疗
公开(公告)号：EP2621279A1
公开(公告)日：2013-08-07
申请号：EP11833017.4
申请日：2011-09-28
发明人： COBURN, Craig, A. , LAVEY, Brian, J. , DWYER, Michael, P. , KOZLOWSKI, Joseph, A. , ROSENBLUM, Stuart, B.
CPC分类号： A61K31/553 , A61K31/4178 , A61K31/5517 , A61K45/06 , C07D403/14 , C07D405/14 , C07D487/04 , C07D493/04 , C07D498/04 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/395
摘要： The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A′, B, G, R1, U, V, W, W′, X, X′, Y and Y′ are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.032 秒)
